Trials / Completed
CompletedNCT00638989
A Study to Assess Bioavailability and Pharmacokinetics of CAT- 354
An Open-Label, Parallel-Group, Bioavailability Study to Assess the Pharmacokinetics of CAT-354 Following Subcutaneous and Intravenous Administration
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- MedImmune LLC · Industry
- Sex
- Male
- Age
- 19 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
To compare bioavailability and pharmacokinetics of CAT-354 following subcutaneous administration compared with intravenous administration.
Detailed description
To compare the bioavailability and pharmacokinetics of CAT-354 following subcutaneous administration of 150 milligram (mg) and 300 mg compared with 150 mg given intravenously.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CAT-354 150 mg (intravenous) | A single dose of CAT-354 150 milligram (mg) intravenous infusion over 30 minutes on Day 0. |
| BIOLOGICAL | CAT-354 150 mg (subcutaneous) | A single dose of CAT-354 150 mg injection subcutaneously on Day 0. |
| BIOLOGICAL | CAT-354 300 mg (subcutaneous) | A single dose of CAT-354 300 mg injection subcutaneously on Day 0. |
Timeline
- Start date
- 2008-04-11
- Primary completion
- 2008-06-07
- Completion
- 2008-06-07
- First posted
- 2008-03-19
- Last updated
- 2017-05-04
- Results posted
- 2017-05-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00638989. Inclusion in this directory is not an endorsement.